Another Award for the Sturdza Family Fund
30.6.2022 10:00:00 EEST | Business Wire | Press release
Having reached its third anniversary in December 2021 the Sturdza Family Fund and the investment team became eligible for consideration by a number of the industry’s independent rating agencies.
To date, the Fund has received 4-star and 5-star Morningstar ratings (depending on the share class); a 5-Globe ‘High’ Morningstar Sustainability Rating (putting the Fund in the top 10% of all Funds within its peer group) and three of the investment team have been rated by Citywire. These all speak to the quality of the management of the Fund, particularly from a risk-adjusted perspective.
We are pleased to advise therefore the Fund has received further recognition, from FundsPeople. They have classified the Sturdza Family Fund as one of their "Distinguished Investment Products of the Year" within their 2022 Fund ratings in Italy and Spain.
The Sturdza Family Fund has been recognised for the consistency of the returns, with reference tovolatility versus its Morningstar-defined peer group. Additional information regarding FundsPeople’s assessment methodology is provided below.
About the Sturdza Family Fund
The Fund was launched to capitalise on Eric Sturdza’s long-term approach to investing, with a focus on high growth and stable companies, whilst seeking to reduce volatility through a diversified flexible allocation portfolio. The Fund is an important component in the Sturdza Family’s own wealth management strategy.
Accordingly, the team is composed of experienced and complementary managers and advisers, with diverse backgrounds and in-depth knowledge of their respective asset classes, to support the delivery of the investment objective over the long term.
Today the team consists of seven individuals, including Eric and Constantin Sturdza. Through this Fund, we seek to give long-term investors the opportunity to invest alongside the Sturdza family ensuring a true alignment of interests.
Commenting on the recognition from FundsPeople, Constantin Sturdza said: “We are delighted that the Sturdza Family Fund has been recognised by FundsPeople for the risk-adjusted returns that have been achieved since inception in 2018. The macro environment has been volatile and unpredictable at times; however, we as a team are proud that the strategy has achieved our objective, based on long-term principles, with a focus on value creation.
We are continuously looking at ways to enhance our approach and adapt to the investment environment we face, with the aim of ensuring we continue to serve our clients in a unique way and in doing so maintain a total and relatively unparalleled alignment of interest as cornerstone investors ourselves.”
The FundsPeople Rating Methodology
For seven years, FundsPeople has been evaluating funds based on three criteria to identify the products, in each market, that have demonstrated consistent results compared to their peer group and are considered to be among the best bets according to fund selectors or have a significant heritage in the specific market. FundsPeople believes that a fund that meets at least one of these criteria is worthy of recognition in the so-called FundsPeople Ratings.
As noted, the Sturdza Family Fund was selected based on the consistency of the risk-adjusted returns. These are analysed by the team at FundsPeople utilising their own quantitative model which identifies the most consistent funds within each category (Morningstar Category).
The initial stage of the process considers the entire universe of funds available for sale in the relevant market, with profitability data for more than three years at the end of the relevant calendar year (2021 in this instance). Only the oldest share class that is available for sale in the market under consideration is utilised in this regard.
The focus of the team at FundsPeople is to identify how each fund has behaved based on two variables: profitability and volatility, in base currency terms. They compare each fund within the peer group using two scorecards.
The first considers cumulative profitability and volatility data over three and five years; whilst the second considers these metrics over the last five calendar years (2017, 2018, 2019, 2020 and 2021). In both cases, profitability and volatility are weighted 65% / 35% respectively. Each scorecard ranks the funds within the peer group, with those within the first quintile receiving a rating.
Get in touch
For further information regarding the Sturdza Family Fund, the investment team or to receive additional materials please contact info@ericsturdza.com or visit the fund page on ericsturdza.com.
The views and statements contained herein are those of Banque Eric Sturdza SA in their capacity as Investment Advisers to the Fund as of 27/06/2022 and are based on internal research and modelling. Please refer to ericsturdza.com for full disclaimers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005073/en/
Contact information
Viali Munteanu
ericsturdzainvestments@cognitomedia.com
07547819438
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
